Researchers from the National Institutes of Health and Columbia University screened more than 2,800 compounds in 61 Plasmodium falciparum lines, identifying potential anti-malarial agents and using genetic approaches to find loci related to treatment response differences in the malaria parasite.
"What we're going to need to fully take advantage of Watson is to have the genetic and epigenetic information of patients so that the Watson program will be able to utilize and organize that also in medical decision making," said a researcher involved with IBM's efforts to develop an artificial intelligence system that can help doctors diagnose patients accurately and quickly.
There has “been a tremendous shift towards using regulatory, integrative genomic, and kinetic models to understand the biology of drug development [and] disease and using modeling and simulation to predict what the cell is doing.”
The company is currently collaborating with Ian Lipkin's lab at Columbia University to co-develop a set of MassTag PCR panels for infectious disease screening that it plans to commercialize some time in the next year.
SRU Biosystems, California Institute of Technology, Intelligent Medical Devices, Columbia University, Tufts University, Edelmira Cabezas, University of Washington, Illumina, Stanford University, Agilent Technologies